Literature DB >> 17763029

The evolution of botulinum neurotoxin type A for cosmetic applications.

Jean Carruthers1, Alastair Carruthers.   

Abstract

Very few pharmaceutical preparations share an evolutionary history as remarkable as that of botulinum neurotoxin (BoNT). The exotoxin of the organism Clostridium botulinum, once feared as a terrible poison, has been reborn as a highly regarded and widely used therapeutic and aesthetic agent. In less than two decades since the report of the success of BoNT type A (BoNTA) in reducing glabellar lines, injection of this product has become the most common non-surgical cosmetic procedure performed in the USA and worldwide. In addition to temporarily eliminating rhytids by muscle weakening, other dermatologic applications of BoNTA include correcting facial asymmetries and treating hyperhidrosis. Although BOTOX is the most clinically substantiated and published of the BoNTA preparations, other BoNTA products, as well as a BoNT type B product, are available in some parts of the world, and others are in development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17763029     DOI: 10.1080/14764170701411470

Source DB:  PubMed          Journal:  J Cosmet Laser Ther        ISSN: 1476-4172            Impact factor:   2.247


  7 in total

Review 1.  [Management and prevention of adverse events in esthetic interventions].

Authors:  D Hartmann; M Heppt; G G Gauglitz
Journal:  Hautarzt       Date:  2015-10       Impact factor: 0.751

Review 2.  Botulinum toxin in the management of blepharospasm: current evidence and recent developments.

Authors:  Amy Hellman; Diego Torres-Russotto
Journal:  Ther Adv Neurol Disord       Date:  2015-03       Impact factor: 6.570

Review 3.  Comparison and overview of currently available neurotoxins.

Authors:  Thomas J Walker; Steven H Dayan
Journal:  J Clin Aesthet Dermatol       Date:  2014-02

4.  A Novel OnabotulinumtoxinA Treatment Technique to Obtain Predictable Outcomes in Eyebrow Position and Shape.

Authors:  Maria Angelo-Khattar
Journal:  Clin Cosmet Investig Dermatol       Date:  2020-10-27

5.  [Botulinum toxin in dermatology].

Authors:  W G Philipp-Dormston
Journal:  Hautarzt       Date:  2014-02       Impact factor: 0.751

6.  Outcomes of a regional variant of botulinum toxin type A in the treatment of essential blepharospasm and hemifacial spasms: A retrospective study.

Authors:  V Maneksha; Sabyasachi Chakrabarty; Meghana Tanwar; Madhavi Ramanatha Pillai
Journal:  Indian J Ophthalmol       Date:  2021-10       Impact factor: 1.848

7.  Neurotoxin Impurities: A Review of Threats to Efficacy.

Authors:  Je-Young Park; Owen Sunga; Rungsima Wanitphakdeedecha; Jürgen Frevert
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-01-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.